阿托伐他汀对高血压病患者左室舒张功能及C反应蛋白的影响

目的 观察短期应用阿托伐他汀对高血压病患者左室舒张功能及C反应蛋白(CRP)的影响.方法 选择高血压病患者87例,分为阿托伐他汀组(49例)及对照组(38例).对照组给予常规降压药物治疗,治疗组在常规治疗基础上加用阿托伐他汀.测定治疗前后二尖瓣舒张早期峰值流速(E)及减速时间(DT)、舒张晚期峰值流速(A)、舒张早期与舒张晚期峰值流速之比(E/A)、等容舒张时间(IVRT)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)及CRP的水平.结果 治疗12周后治疗组与治疗前比较差异有统计学意义(P＜0.05),E峰增高,A峰降低,E/A比值增加,IVRT缩短,DT缩短(P＜0.05),与对照组比较差异均有统计学意义(P＜0.05).治疗组CRP、LDL-C、TC水平较治疗前显著降低(P＜0.05),与对照组比较差异有统计学意义(P＜0.05).治疗前后治疗组TC、LDL-C水平与E/A均无相关性(P＞0.05).结论 短期应用阿托伐他汀可降低高血压病患者CRP水平,改善左室舒张功能. Abstract： Objective To observe the effects of atorvastatin on C - reactive protein and left ventricular diastolic function in patients with essential hypertension.Methods Eighty - seven patients with essential hypertension were randomly divided into two groups, including control group and atorvastatin group.The control group was treated with normal therapy, whereas atorvastatin group was treated with normal therapy and atorvastatin.The early filling velocity of the E wave, peak A wave velocity, E/A ratio, isovolumic relaxation time(IVRT), DT, LDL - C, TC and CRP were observed before and after treatment.Results Compared with the control group, peak E wave velocity of atorvastatin group was increased,peak A wave velocity decreased, E/A ratio increased, IVRT and DT shortened, the level of LDL -C ,TC and CRP decreased(P ＜0.05).Before and after treatment of atorvastatin group there was no correlationship between the level of LDL - C, TC and CRP and E/A.Conclusions Short - term application of atorvastatin can decrease the level of CRP in patients with essential hypertension, and improve the left ventricular diastolic function.     

老年高血压病合并射血分数正常的心力衰竭患者血浆脑钠肽水平的变化及药物干预

目的 探讨老年高血压病合并射血分数正常的心力衰竭(HF-NEF)患者血浆脑钠肽(BNP)水平的变化以及缬沙坦(代文)对其心功能的影响.方法 测定40例老年高血压病合并HF-NEF患者(心力衰竭组)和30例高血压病心功能正常的老年患者(对照组)血浆BNP水平和心脏彩超多项指标.将40例心力衰竭患者随机分为常规治疗组20例和代文治疗组20例,治疗前后对比血浆BNP水平及心脏彩超多项指标.结果 老年高血压病合并HF-NEF患者血浆BNP浓度显著高于对照组(P＜0.01),且随着NYHA心功能分级程度的加重而显著增高(P＜0.01).治疗6个月后,代文治疗组血浆BNP水平以及反映左室形态和舒张功能的指标明显改善(P＜0.05).临床疗效评定总有效率为90%,与常规治疗组比较差异有统计学意义(P＜0.05).结论 老年高血压病合HF-NEF患者血浆BNP水平随心力衰竭严重程度的加重而显著升高,代文可以改善左室舒张功能,血浆BNP水平对诊断老年高血压病合并HF-NEF及评价疗效有重要作用.     

妊娠期高血压疾病与血钙水平的相关性研究

目的探讨妊娠期高血压疾病与母体血清钙水平的关系。方法检测102例妊娠期高血压疾病患者产前外周血清钙含量,将100例正常晚期妊娠妇女及100例非妊娠健康妇女作为对照组进行比较。结果妊娠期高血压疾病组低钙例数为89例,占87.25%,与妊娠对照组及非妊娠对照组相比,差异有统计学意义(P<0.05)。妊娠对照组的血钙水平为(2.14±0.30)mmol/L,与非妊娠对照组相比降低,但差异无统计学意义(P>0.05);而妊娠期高血压疾病组的血钙水平为(1.87±0.28)mmol/L,与妊娠对照组及非妊娠对照组相比显著降低,差异均有统计学意义(P<0.05)。结论母体血清钙含量降低可能在妊娠期高血压疾病病理生理变化中起重要作用,在监测血钙水平的同时,可进行有针对性的钙剂治疗。     

重度妊娠期高血压合并低蛋白血症临床分析

目的：探讨重度妊娠期高血压疾病（HDCP）合并低蛋白血症（HP）的发生、处理、治疗及预后。方法：比较25例重度HDCP合并低蛋白血症患者妊娠水肿、各孕周血清清蛋白测定结果，并进行围生儿结局的比较，分娩方式、新生儿体重的比较，分析HDCP合并HP的综合治疗措施。结果：严重HP是重度HDCP各种并发症中较常见的一种，及时纠正有利于母婴健康。结论：重度HDCP患者常合并重度HP，产前检查要注意严重HP的纠正，并采用综合治疗，对重度HDCP孕产妇及新生儿的有益。     

妊娠期高血压疾病的血清学研究进展

妊娠期高血压疾病严重危害母儿健康,其发病机制至今仍不明确,随着科技的进步,对其病因的研究已经进入到细胞因子水平。近年来细胞因子及血管内皮细胞损伤与妊娠期高血压疾病的关系备受关注,本文通过总结国内外文献中对妊娠期高血压孕妇血清中一些细胞因子水平的改变,探讨其是否与妊娠期高血压疾病的发病、疾病进展密切相关,为妊娠期高血压疾病的病因学研究和临床研究提供思路。     

硫酸镁联合小剂量阿司匹林治疗妊娠高血压41例疗效观察

目的探讨硫酸镁联合小剂量阿司匹林治疗妊娠高血压疾病的临床效果。方法选择我院2007年7月至2010年7月妊娠高血压疾病患者82例,随机分为观察组和对照组。对照组患者给予25%硫酸镁每天20g静脉滴注,控制滴速为1～1.5g/h;观察组在对照组应用硫酸镁的基础上给予阿司匹林每天50mg口服。观察两组患者在治疗72h后血压、呼吸、心率、尿量等改变情况。结果观察组总有效率显著高于对照组,差异有统计学意义（P〈0.05）;观察组治疗后血黏度、血细胞压积、24h尿蛋白定量、S/D和RI分别与对照治疗后比较,差异有统计学意义（P〈0.05）。结论硫酸镁联合小剂量阿司匹林能够显著改善妊娠高血压疾病患者临床症状和体征,有利于胎儿发育,临床效果显著。     

Endogenous ouabain in hypertensive disorder complicating pregnancy

Summary Expression of endogenous ouabain in placenta and the concentrations of serum ET-1 and NO were examined in 30 patients with hypertensive disorder complicating pregnancy (HDCP) and 30 healthy pregnant women to investigate the effect of endogenous ouabain on HDCP. Compared with the healthy pregnant group, the expression of endogenous ouabain dramatically increased in the HDCP groups (P<0.01). There was a significantly positive correlation between the expression of endogenous ouabain with ET-1 (r=0.5567, P<0.01), while the correlation of endogenous ouabain and NO was significantly negative (r=−0.6895, P<0.01). As expected, the correlation between ET-1 and NO was negative (r=−0.7796, P<0.01). ET-1 concentrations of maternal and cord sera in HDCP groups were significantly higher in comparison with healthy pregnant group (P<0.01). On the contrast, NO concentrations were much lower in the maternal and cord sera of HDCP groups as compared with healthy pregnant group (P<0.01). Our data suggest that endogenous ouabain is directly involved in the nosogenesis of HDCP, with accompanying decreased NO and the elevated of ET-1. This project was supported by grants from the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (NO: 200414519001).     

Endogenous Ouabain in Hypertensive Disorder Complicating Pregnancy

Expression of endogenous ouabain in placenta and the concentrations of serum ET-1 and NO were examined in 30 patients with hypertensive disorder complicating pregnancy (HDCP) and 30 healthy pregnant women to investigate the effect of endogenous ouabain on HDCP. Compared with the healthy pregnant group, the expression of endogenous ouabain dramatically increased in the HDCP groups (P<0.01). There was a significantly positive correlation between the expression of en- dogenous ouabain with ET-1 (r= 0.5567, P<0.01), while the correlation of endogenous ouabain and NO was significantly negative (r=-0.6895, P<0.01). As expected, the correlation between ET-1 and NO was negative (r=-0.7796, P<0.01). ET-1 concentrations of maternal and cord sera in HDCP groups were significantly higher in comparison with healthy pregnant group (P<0.01). On the con- trast, NO concentrations were much lower in the maternal and cord sera of HDCP groups as com- pared with healthy pregnant group (P<0.01). Our data suggest that endogenous ouabain is directly involved in the nosogenesis of HDCP, with accompanying decreased NO and the elevated of ET-1.     

妊娠期高血压疾病与胎儿生长受限相关性研究

目的:探讨妊娠期高血压疾病与胎儿生长受限的相关性。方法:收集妊高症患者350例,统计患者妊高症诊断时间、妊娠终止周数、胎儿窒息与死亡情况等临床资料,分析妊娠期高血压疾病与胎儿生长受限的关系。结果:350例妊高症患者合并胎儿生长受限58例(16.6%)。于妊娠34周前诊断为妊娠期高血压的患者有52.23%合并胎儿生长受限,其发生率显著高于妊娠34周后确诊为妊娠期高血压者的8.13%。子痫前期重度患者胎儿生长受限的发病率(30.1%)要高于妊娠期高血压及子痫前期轻度患者(11.7%和8.2:%)。子痫前期轻度和子痫前期重度发生死胎的比例(18.91%和7.69%)高于妊娠期高血压(0),子痫前期重度新生儿窒息和围产儿死亡的发生率(51.35%和45.95%)要高于妊娠期高血压和子痫前期轻度的患者(25%,12.5%和23.07%,15.38%),差异有统计学意义。结论妊娠期高血压疾病是引起胎儿生长受限的相关因素之一,积极预防、合理治疗妊娠期高血压疾病是降低胎儿生长受限发病率、改善围产儿预后的重要手段。     

不同类型妊娠期高血压疾病对妊娠结局的影响

目的探讨不同类型妊娠期高血压疾病（DHCP）对妊娠结局的影响。方法采用简单抽样法,选取合并不同类型DHCP孕妇168例为观察组,随机选取同时期的正常孕妇168例为对照组,详细记录、统计并分析产妇、胎儿及新生儿的不良结局。结果观察组围产妇不良结局总发生率为48.81%,对照组3.57%。2组产妇除妊娠期高血压心脏病并发症发生率差异无统计学意义（P>0.05）外,观察组产妇胎盘早剥等并发症发生率均高于对照组（P < 0.05~P < 0.01）,观察组产妇合并2种并发症发生率高于对照组（P < 0.01）,而2组产妇合并3种并发症发生率差异无统计学意义（P>0.05）。观察组胎儿不良结局总发生率为58.42%,对照组为6.90%。观察组胎儿死亡、宫内窘迫、胎儿生长受限发生率均高于对照组（P < 0.05~P < 0.01）,观察组胎儿合并2种并发症发生率高于对照组（P < 0.01）,而2组胎儿合并3种并发症发生率差异无统计学意义（P>0.05）。观察组围新生儿不良结局总发生率为46.55%,对照组为4.93%。观察组新生儿窒息、小于胎龄儿发生率均高于对照组（P < 0.01）,观察组新生儿合并2种并发症发生率高于对照组（P < 0.01）,而2组新生儿死亡及合并3种并发症发生率差异无统计学意义（P>0.05）。妊娠期高血压、子痫前期、子痫、妊娠合并慢性高血压和慢性高血压并发子痫前期围产妇胎盘早剥、胎儿死亡、新生儿死亡等不良结局发生率差异均无统计学意义（P>0.05）。结论DHCP严重影响围产妇母婴预后,且随着疾病进程的发展,影响逐渐增加。临床应加强筛查,尽早发现和干预,改善母婴预后质量。     

高龄孕妇妊娠期高血压疾病的围生结局分析

目的：探讨高龄孕妇并发妊娠高血压疾病对围生结局的影响。方法：对我院2005年12月～2008年12月收治的92例35岁以上的妊娠期高血压疾病孕妇（观察组）与同期分娩的35岁以下的妊娠期高血压疾病孕妇115例（对照组）进行对照分析。结果：观察组子痫前期、子痫的发生率与对照组比较,有显著性差异（P〈0.01）; 观察组早产、胎儿生长受限、围生儿死亡的发生率比对照组高（P〈0.05）。两组新生儿窒息、胎儿窘迫的发生率比较,无显著性差异（P〉0.05）。结论：高龄孕妇并发妊娠期高血压疾病病情重,对母儿危害大,恰当的围生期管理并适时终止妊娠是治疗成功的关键。     

交感神经活动与妊娠期高血压疾病

妊娠期高血压疾病是产科常见并发症,严重威胁母婴健康,是导致孕产妇及围生儿病率及死亡的重要原因之一。其病因及发病机制尚未完全明确,近年来国外研究发现交感神经活动亢进在妊娠期高血压疾病发病机制中起到一定作用。本文就近年来交感神经活动与妊娠期高血压疾病关系方面的研究作一综述。